Medical institute Albert Einstein College of Medicine and Montefiore Health System on Friday announced a seven-year grant, valued at USD23m, to study HIV and the chronic illnesses that often accompany HIV infection, including cardiovascular and lung disease, diabetes and cancer.
The grant, titled "Clinical research sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS)," was awarded by the National Heart, Lung and Blood Institute, part of the from the National Institutes of Health.
This new NIH grant is based on the scientific and clinical research from the 26-year-old Women's Interagency HIV Study (WIHS), a multi-centre study of women who are either living with HIV or at risk for HIV infection. The NIH has merged the WIHS study with a comparable parallel study in men known as the Multicenter AIDS Cohort Study, or MACS. These studies enrolled thousands of participants and spurred more than 2,300 publications on HIV-related topics.
Under the new MACS/WIHS Combined Cohort Study, the companies will continue using information from participants in the earlier studies and will enroll an additional 2,500 men and women, including people without HIV. It will focus on the chronic conditions that now affect people living with HIV, rather than the HIV infection itself.
According to the companies, the new study will allow researchers to investigate the impact of age, race, ethnicity and health disparities on HIV-related comorbidities and HIV disease progression. The Bronx site will enroll between 150 and 200 participants.Study participants will undergo comprehensive annual exams and tests.
Dr Anastos has led scientific and clinical research at the Einstein and Montefiore Bronx WIHS site. Anjali Sharma, MD, MS, co-principal investigator, associate professor of medicine at Einstein and an internist and infectious disease physician at Montefiore, joined the Bronx WIHS in 2013.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes